Carlos Rangel-Pelaez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Rangel-Pelaez has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ariane Loraine Herrick
Centre for Musculoskeletal Research, University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester
3 shared publications - Lorenzo Beretta
Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
3 shared publications - Marialbert Acosta-Herrera
Institute of Parasitology and Biomedicine López-Neyra, Spanish National Research Council, Granada, Spain
3 shared publications - Martin Kerick
Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain
3 shared publications Nicolas Hunzelmann
Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany
3 shared publications- Oliver Distler
Department of Rheumatology University Hospital Zurich, University of Zurich Zurich Switzerland
3 shared publications
Latest Publications
- Open Access
- 8 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud’s phenomenon
Objective: Raynaud’s phenomenon (RP) is the first noticeable symptom of systemic sclerosis (SSc), appearing even years before other signs. Vascular and immune pathways, hallmarks in SSc pathogenesis, are implicated in primary RP. Hence, we aimed to define the shared genetic architecture between these conditions to explore pathogenic mechanisms and whether pleiotropic loci could help identify primary RP patients at increased genetic risk of developing SSc. Methods: We analysed genome-wide association study (GWAS) summary statistics for primary RP (4 986 cases and 850 981 controls) and SSc (10 654 cases and 18 043 controls). We performed a cross-trait meta-analysis (∼8.6M single nucleotide polymorphisms) to identify variants associated with both diseases. Functional annotation was used to prioritise potential causal genes. We also constructed a polygenic risk score (PRS) to assess clinical implications. Results: Beyond the well-known HLA associations, we identified five additional pleiotropic loci, including MEOX2 as a novel association for both traits with opposing effects, ADRA2A representing a novel genetic factor for SSc, and IL12A, NFKB1 and TNIP1 as novel loci for primary RP. Functional annotation highlighted vascular and inflammatory pathways. Finally, the PRS model shows modest discrimination (area under the curve = 0.57). However, it allows the identification of primary RP individuals at high genetic risk of developing SSc (75th percentile, relative risk =1.29 [95% CI 1.02, 1.62]; P-value= 3.58 × 10−2). Conclusion: This study reveals a genetic link between primary RP and SSc, identifying five novel pleiotropic loci and supporting the potential of genetic profiling for early risk assessment and personalised monitoring strategies.
- 8 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Open AccessNovel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud’s phenomenon
Objective: Raynaud’s phenomenon (RP) is the first noticeable symptom of systemic sclerosis (SSc), appearing even years before other signs. Vascular and immune pathways, hallmarks in SSc pathogenesis, are implicated in primary RP. Hence, we aimed to define the shared genetic architecture between these conditions to explore pathogenic mechanisms and whether pleiotropic loci could help identify primary RP patients at increased genetic risk of developing SSc. Methods: We analysed genome-wide association study (GWAS) summary statistics for primary RP (4 986 cases and 850 981 controls) and SSc (10 654 cases and 18 043 controls). We performed a cross-trait meta-analysis (∼8.6M single nucleotide polymorphisms) to identify variants associated with both diseases. Functional annotation was used to prioritise potential causal genes. We also constructed a polygenic risk score (PRS) to assess clinical implications. Results: Beyond the well-known HLA associations, we identified five additional pleiotropic loci, including MEOX2 as a novel association for both traits with opposing effects, ADRA2A representing a novel genetic factor for SSc, and IL12A, NFKB1 and TNIP1 as novel loci for primary RP. Functional annotation highlighted vascular and inflammatory pathways. Finally, the PRS model shows modest discrimination (area under the curve = 0.57). However, it allows the identification of primary RP individuals at high genetic risk of developing SSc (75th percentile, relative risk =1.29 [95% CI 1.02, 1.62]; P-value= 3.58 × 10−2). Conclusion: This study reveals a genetic link between primary RP and SSc, identifying five novel pleiotropic loci and supporting the potential of genetic profiling for early risk assessment and personalised monitoring strategies.
- Open Access
- 18 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (4) , 904-913
Distinct Effects of Complement C4A and C4B Copy Numbers in Systemic Sclerosis Serological and Clinical Subtypes
Objective: Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. The variable copy number (CN) of C4 genes and retroviral human endogenous retrovirus K (HERV‐K) element influence its function. Given the relationship of C4 CN with systemic sclerosis (SSc) risk, we assessed associations with SSc clinical and serologic subtypes. Methods: We compared imputed C4 CNs across SSc subgroups (4,049 anticentromere positive [ACA + ]; 2,200 anti–topoisomerase I [ATA + ]; 577 anti‐RNA polymerase [ARA + ]; 1,078 triple‐negative [TN] patients; 6,295 limited cutaneous SSc [lcSSc]; and 2,946 diffuse cutaneous SSc [dcSSc]) and 17,991 controls. We evaluated associations with SSc subtypes, identifying C4 ‐independent HLA alleles. Results: Lower C4 CN and higher HERV‐K CN were associated with increased risk in all SSc subgroups. ATA + patients showed the strongest association, particularly with C4A (odds ratio = 1.88), and differences in C4A CN association were more pronounced between autoantibody subgroups (ATA + vs ACA + , P = 4 × 10 −11 ) than between clinical subgroups (dcSSc vs lcSSc, P = 1 × 10 −4 ). In ACA + patients, only low C4B CN showed a significant association to SSc risk ( P = 1.23 × 10 −5 ). We also observed sex‐biased associations: dcSSc, ATA + , and ARA + male patients showed stronger effects for C4A and ACA + and lcSSc female patients for C4B . Finally, our results suggest that the HLA alleles associated with SSc subgroups are independent of C4 CN. Conclusion: This study highlights distinct genetic contributions of C4A and C4B in SSc subtypes susceptibility. Our findings suggest that lower C4 CNs, particularly C4A , increase the risk of the severe dcSSc subtype, potentially through a mechanism involving immune complex clearance. image
- 18 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (4) , 904-913
Open AccessDistinct Effects of Complement C4A and C4B Copy Numbers in Systemic Sclerosis Serological and Clinical Subtypes
Objective: Complement component 4 (C4), encoded by C4A and C4B within the major histocompatibility complex (MHC) on chromosome 6, regulates the immune response and clears immune complexes. The variable copy number (CN) of C4 genes and retroviral human endogenous retrovirus K (HERV‐K) element influence its function. Given the relationship of C4 CN with systemic sclerosis (SSc) risk, we assessed associations with SSc clinical and serologic subtypes. Methods: We compared imputed C4 CNs across SSc subgroups (4,049 anticentromere positive [ACA + ]; 2,200 anti–topoisomerase I [ATA + ]; 577 anti‐RNA polymerase [ARA + ]; 1,078 triple‐negative [TN] patients; 6,295 limited cutaneous SSc [lcSSc]; and 2,946 diffuse cutaneous SSc [dcSSc]) and 17,991 controls. We evaluated associations with SSc subtypes, identifying C4 ‐independent HLA alleles. Results: Lower C4 CN and higher HERV‐K CN were associated with increased risk in all SSc subgroups. ATA + patients showed the strongest association, particularly with C4A (odds ratio = 1.88), and differences in C4A CN association were more pronounced between autoantibody subgroups (ATA + vs ACA + , P = 4 × 10 −11 ) than between clinical subgroups (dcSSc vs lcSSc, P = 1 × 10 −4 ). In ACA + patients, only low C4B CN showed a significant association to SSc risk ( P = 1.23 × 10 −5 ). We also observed sex‐biased associations: dcSSc, ATA + , and ARA + male patients showed stronger effects for C4A and ACA + and lcSSc female patients for C4B . Finally, our results suggest that the HLA alleles associated with SSc subgroups are independent of C4 CN. Conclusion: This study highlights distinct genetic contributions of C4A and C4B in SSc subtypes susceptibility. Our findings suggest that lower C4 CNs, particularly C4A , increase the risk of the severe dcSSc subtype, potentially through a mechanism involving immune complex clearance. image
- Open Access
Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease
Objective: The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date. Methods: Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls. Results: Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance. Conclusion: Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the MUC5B promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture.
Open AccessAssessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease
Objective: The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date. Methods: Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls. Results: Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance. Conclusion: Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the MUC5B promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture.